Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
HLA-DOB Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DO beta chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DOB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DOA Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DO alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DOA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DMB Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DM beta chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DMB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DMA Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DM alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DMA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-C Biologics Sequence Review Report 2026: HLA class I histocompatibility antigen, C alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-B Biologics Sequence Review Report 2026: HLA class I histocompatibility antigen, B alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-A Biologics Sequence Review Report 2026: HLA class I histocompatibility antigen, A alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HAVCR1 Biologics Sequence Review Report 2026: Hepatitis A virus cellular receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HAVCR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GPR55 Biologics Sequence Review Report 2026: G protein-coupled receptor 55 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of GPR55 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GPR52 Biologics Sequence Review Report 2026: G protein-coupled receptor 52 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of GPR52 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GPR35 Biologics Sequence Review Report 2026: G protein-coupled receptor 35 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of GPR35 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GPR26 Biologics Sequence Review Report 2026: G protein-coupled receptor 26 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of GPR26 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.